All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

Panelists discuss how the all-oral regimen of oral azacitidine and venetoclax offers a promising treatment option for newly diagnosed and relapsed/refractory acute myeloid leukemia, highlighting its potential to improve patient outcomes and simplify treatment administration.

Now Viewing

EP: 1.All Oral Regimen of Oral Azacitidine and Venetoclax for Newly Diagnosed and Relapsed/Refractory AML

EP: 2.AUGMENT-101 Updated Results and Longer Follow-Up of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia

EP: 3.Debate: What Is the Best Posttransplant Follow-Up - Maintenance vs Close Monitoring With Laboratory Testing

EP: 4.Debate: Treating Patients With Relapsed/Recurrent AML - MENIN Inhibitors vs Standard of Care

EP: 5.Clinical Scenario: Newly Diagnosed AML With an NPM1 Mutation

EP: 6.Clinical Scenario: TP53- Mutant AML

Recent Videos